Alnefeesi Yazen, Siegel Ashley, Lui Leanna M W, Teopiz Kayla M, Ho Roger C M, Lee Yena, Nasri Flora, Gill Hartej, Lin Kangguang, Cao Bing, Rosenblat Joshua D, McIntyre Roger S
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Front Psychiatry. 2021 Feb 10;11:621773. doi: 10.3389/fpsyt.2020.621773. eCollection 2020.
The prevalence and etiology of COVID-19's impact on brain health and cognitive function is poorly characterized. With mounting reports of delirium, systemic inflammation, and evidence of neurotropism, a statement on cognitive impairment among COVID-19 cases is needed. A substantial literature has demonstrated that inflammation can severely disrupt brain function, suggesting an immune response, a cytokine storm, as a possible cause of neurocognitive impairments. In this light, the aim of the present study was to summarize the available knowledge of the impact of COVID-19 on cognition (i.e., herein, we broadly define cognition reflecting the reporting on this topic in the literature) during the acute and recovery phases of the disease, in hospitalized patients and outpatients with confirmed COVID-19 status. A systematic review of the literature identified six studies which document the prevalence of cognitive impairment, and one which quantifies deficits after recovery. Pooling the samples of the included studies (total sample = 644) at three standards of quality produced conservative estimates of cognitive impairment ranging from 43.0 to 66.8% prevalence in hospitalized COVID-19 patients only, as no studies which report on outpatients met criteria for inclusion in the main synthesis. The most common impairment reported was delirium and frequent reports of elevated inflammatory markers suggest etiology. Other studies have demonstrated that the disease involves marked increases in IL-6, TNFα, and IL-1β; cytokines known to have a profound impact on working memory and attention. Impairment of these cognitive functions is a characteristic aspect of delirium, which suggests these cytokines as key mediators in the etiology of COVID-19 induced cognitive impairments. Researchers are encouraged to assay inflammatory markers to determine the potential role of inflammation in mediating the disturbance of cognitive function in individuals affected by COVID-19.
新冠病毒病(COVID-19)对大脑健康和认知功能影响的患病率及病因目前尚不明确。随着关于谵妄、全身炎症以及神经嗜性证据的报道不断增加,有必要就COVID-19病例中的认知障碍发表一份声明。大量文献表明,炎症可严重扰乱大脑功能,提示免疫反应即细胞因子风暴可能是神经认知障碍的一个原因。鉴于此,本研究的目的是总结COVID-19在疾病急性期和康复期对确诊为COVID-19的住院患者和门诊患者认知(即在此,我们广泛定义认知,以反映文献中关于该主题的报道)影响的现有知识。一项系统的文献综述确定了六项记录认知障碍患病率的研究,以及一项对康复后缺陷进行量化的研究。将纳入研究的样本(总样本 = 644)按照三个质量标准进行合并,仅对住院COVID-19患者的认知障碍患病率进行了保守估计,范围在43.0%至66.8%之间,因为没有关于门诊患者的研究符合纳入主要综合分析的标准。报告的最常见障碍是谵妄,且频繁有炎症标志物升高的报告提示了病因。其他研究表明,该疾病涉及白细胞介素-6(IL-6)、肿瘤坏死因子α(TNFα)和白细胞介素-1β(IL-1β)的显著增加;这些细胞因子已知对工作记忆和注意力有深远影响。这些认知功能的损害是谵妄的一个特征性方面,这表明这些细胞因子是COVID-19诱导的认知障碍病因中的关键介质。鼓励研究人员检测炎症标志物,以确定炎症在介导受COVID-19影响个体认知功能障碍中的潜在作用。